

## FOSTAMATINIB tablets (Tavlesse® ▼) for the treatment of refractory chronic immune thrombocytopenia

The Pan Mersey Area Prescribing Committee does not recommend the prescribing of FOSTAMATINIB tablets (Tavlesse® ▼) for the treatment of refractory chronic immune thrombocytopenia in accordance with NICE TA759.

### BLACK

[NICE technology appraisal \(TA\) 759](#) does not recommend the use of fostamatinib, within its marketing authorisation for treating refractory chronic immune thrombocytopenia (ITP) in adults.<sup>[1]</sup>

NICE states that fostamatinib would be used in practice at the same point in the treatment pathway as rituximab and mycophenolate, however there is currently no clinical trial evidence that directly compares fostamatinib with rituximab or mycophenolate. Clinical evidence does show that fostamatinib is effective compared with placebo and an indirect comparison shows that fostamatinib works better than rituximab at increasing platelet counts. However, NICE states that the cost-effectiveness estimates for fostamatinib compared with rituximab are higher than what NICE normally considers cost effective, therefore fostamatinib is not recommended for this indication.<sup>[1]</sup>

In the meantime, clinicians should continue to follow national guidance, local pathways and local formulary choices for the treatment of ITP including

- > NHSE Interim Clinical Commissioning Policy: [Thrombopoietin receptor agonists as first line therapy for new or relapsed immune thrombocytopenia in adults and children over the age of 1 year during the COVID-19 pandemic](#) (last updated 14<sup>th</sup> December 2021)
- > Pan Mersey APC statement: [RITUXIMAB \(Truxima® ▼, Rixathon® ▼\) for immune \(idiopathic\) thrombocytopenic purpura](#) (last updated 10<sup>th</sup> February 2020)
- > Pan Mersey APC Formulary: [Chapter 09.01.04 Drugs used in platelet disorders](#)

### References

1. National Institute for Health and Care Excellence. Technology Appraisal 759: [Fostamatinib for treating refractory chronic immune thrombocytopenia](#); 07 January 2022. Accessed online 12 January 2022.

**Note:** Patients who are not eligible for treatment under this statement may be considered on an individual basis where their GP or consultant believes exceptional circumstances exist that warrant deviation from the rule of this policy. In this situation, follow locally defined processes.